{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:31:26Z","timestamp":1792125086379,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jhep.2025.01.040","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:06:11Z","timestamp":1739905571000},"page":"358-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer"],"prefix":"10.1016","volume":"83","author":[{"given":"Jennifer J.","family":"Knox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-9341","authenticated-orcid":false,"given":"Igor S.","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii.","family":"Zubkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-4294","authenticated-orcid":false,"given":"Valeriy","family":"Breder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-4077","authenticated-orcid":false,"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0220-4643","authenticated-orcid":false,"given":"Alan","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin M.","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-2612","authenticated-orcid":false,"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Verdaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-1886","authenticated-orcid":false,"given":"Paul J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"De Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Oelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.01.040_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.currproblcancer.2018.01.003","article-title":"Drug development and clinical trial design in pancreatico-biliary malignancies","volume":"42","author":"Harrington","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jhep.2025.01.040_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11864-013-0237-5","article-title":"Current therapy and future directions in biliary tract malignancies","volume":"14","author":"Ciombor","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jhep.2025.01.040_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/cco.2019.12.07","article-title":"Biliary tract cancers: systemic therapy for advanced disease","volume":"9","author":"Martinez","year":"2020","journal-title":"Chin Clin Onol"},{"key":"10.1016\/j.jhep.2025.01.040_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.01.040_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.01.040_bib6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.01.040_bib7","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2025.01.040_bib8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2025.01.040_bib9","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1038\/s41598-019-44089-3","article-title":"Genome-scale CRISPR\/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031","volume":"9","author":"Sarr","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.01.040_bib10","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1002\/onco.13598","article-title":"A Phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)","volume":"26","author":"McNamara","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2025.01.040_bib11","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-20-4403","article-title":"A phase Ib open-label, dose-escalation study of NUC-1031 in combination with carboplatin for recurrent ovarian cancer","volume":"27","author":"Kazmi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.01.040_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/bjc.2016.83","article-title":"Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy","volume":"114","author":"Moriwaki","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.01.040_bib13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2020-0247","article-title":"NUC-1031\/cisplatin versus gemcitabine\/cisplatin in untreated locally advanced\/metastatic biliary tract cancer (NuTide:121)","volume":"16","author":"McNamara","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhep.2025.01.040_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.01.040_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jhep.2025.01.040_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2014.308","article-title":"Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review","volume":"47","author":"Park","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.jhep.2025.01.040_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.01.040_bib18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.jhep.2025.01.040_bib19","article-title":"SWOG 1815: a Phase III randomized trial of gemcitabine, cisplatin and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.01.040_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a Randomized Phase II Study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:09:29Z","timestamp":1773349769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825000856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0168827825000856"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.01.040","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}